Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Pros and cons of vaccination against disease caused by serogroup B meningococcal...
Journal Information
Vol. 150. Issue 3.
Pages 109-113 (February 2018)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 150. Issue 3.
Pages 109-113 (February 2018)
Review
Pros and cons of vaccination against disease caused by serogroup B meningococcal disease
Pros y contras de la vacunación frente a la enfermedad por meningococo B
Visits
...
Miguel Delgado Rodrígueza,b,
Corresponding author
mdelgado@ujaen.es

Corresponding author.
, Ángela Domínguez Garcíab,c
a División de Medicina Preventiva y Salud Pública, Universidad de Jaén, Jaén, Spain
b Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
c Departamento de Medicina, Universidad de Barcelona, Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Tables (2)
Table 1. Outbreaks of meningococcal B disease in American college campuses where the vaccination has been applied.
Table 2. Cost-effectiveness studies on the serogroup B meningococcal vaccine in newborns, carried out in different countries.
Show moreShow less
Abstract

A vaccine has recently been approved in the EU against meningococcal serogroup B, the main cause of meningococcal disease. There is a fierce debate about the decision regarding a universal vaccination in infants older than 2 months, as recommended by the majority of scientific societies. In western Europe the only country to have included the universal vaccination is the United Kingdom, with a lower incidence of the disease than Ireland. Other countries have also adopted it, such as the Czech Republic, Cuba and certain regions of Italy. Numerous cost-effectiveness studies have been published regarding the vaccination with different assumptions, which have supported the decision not to implant the universal vaccination because it exceeds the will to pay for a health benefit. We discuss the pros and cons of the universal vaccination against meningococcal B, recommended by the Sociedad Española de Pediatría (Spanish Society of Paediatrics), which as yet has not been implemented.

Keywords:
Meningococcal disease
Meningococcal serogroup B
Vaccine
Cost-effectiveness analysis
Resumen

Se ha aprobado recientemente en la UE una vacuna frente al meningococo serogrupo B, principal causante de enfermedad meningocócica. Existe una fuerte discusión sobre la decisión de una vacunación universal en niños mayores de 2 meses, recomendada por la mayoría de las sociedades científicas. En Europa occidental el único país que ha incluido la vacunación universal ha sido el Reino Unido, con una incidencias inferior de la enfermedad a la de Irlanda. Otros países también la han adoptado, como Chequia, Cuba o ciertas regiones de Italia. Se han publicado numerosos estudios de coste-efectividad sobre la vacunación con asunciones diferentes, que han sustentado la decisión de no implantar la vacunación universal al superar la voluntad de pagar por un beneficio de salud. Se discuten los pros y contras de la vacunación universal frente al meningococo B, recomendada por la Sociedad Española de Pediatría, y que no se ha implantado aún.

Palabras clave:
Enfermedad meningocócica
Meningococo serogrupo B
Vacuna
Análisis coste-efectividad

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos